Literature DB >> 15946879

Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population.

Tohru Maeda1, Satoshi Sumi, Akihito Ueta, Yumiko Ohkubo, Tetsuya Ito, Anthony M Marinaki, Yukihisa Kurono, Shinsaku Hasegawa, Hajime Togari.   

Abstract

Inosine triphosphate pyrophosphohydrolase (ITPase) is an enzyme that catalyzes the conversion of inosine triphosphate (ITP) to inosine monophosphate and pyrophosphate. In Caucasian populations it is reported that the frequency of cases showing decreased ITPase activity is 5%. The structure of ITPA gene along with five single nucleotide polymorphisms has been reported in Caucasians. We examined ITPase activity and frequency of two polymorphisms (94C>A and IVS2+21A>C) in 100 Japanese individuals. Among these individuals, we observed that three cases with zero activity were homozygote for 94C>A, and were accompanied by abnormal accumulation of ITP in erythrocytes. The cases included in the low ITPase activity group were heterozygote for 94C>A polymorphism. The activity of the heterozygote cases was approximately 27% of the mean value of the wild type. The allele frequency of the 94C>A polymorphism was 0.155, which was 2.6 times higher than that of the Caucasians (0.06). The IVS2+21A>C was not detected in Japanese cases, although it occurred with a frequency of 0.130 in Caucasians. Furthermore, we identified a novel mutation IVS2+68T>G in intron 2 in the case with the lowest enzyme activity in the 94C>A wild type. Since the frequency of ITPA 94C>A polymorphism is higher in the Japanese population than that in Caucasians, it is more important to examine ITPA 94C>A polymorphism in the Japanese population to prevent thiopurine drug toxicity. Pretherapeutic screening of individuals for ITPA polymorphisms should be considered for safer and more tolerable treatment with thiopurine drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15946879     DOI: 10.1016/j.ymgme.2005.03.011

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  23 in total

1.  Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.

Authors:  Alexander J Thompson; Rosanna Santoro; Valeria Piazzolla; Paul J Clark; Susanna Naggie; Hans L Tillmann; Keyur Patel; Andrew J Muir; Kevin V Shianna; Leonardo Mottola; Daniela Petruzzellis; Mario Romano; Fernando Sogari; Domenico Facciorusso; David B Goldstein; John G McHutchison; Alessandra Mangia
Journal:  Hepatology       Date:  2011-01-10       Impact factor: 17.425

2.  ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

Authors:  Jacques Fellay; Alexander J Thompson; Dongliang Ge; Curtis E Gumbs; Thomas J Urban; Kevin V Shianna; Latasha D Little; Ping Qiu; Arthur H Bertelsen; Mark Watson; Amelia Warner; Andrew J Muir; Clifford Brass; Janice Albrecht; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2010-02-21       Impact factor: 49.962

3.  Gene polymorphisms involved in manifestation of leucopenia, digestive intolerance, and pancreatitis in azathioprine-treated patients.

Authors:  Katerina Wroblova; Michal Kolorz; Marian Batovsky; Vladimir Zboril; Jana Suchankova; Milan Bartos; Boris Ulicny; Igor Pav; Ladislava Bartosova
Journal:  Dig Dis Sci       Date:  2012-04-26       Impact factor: 3.199

Review 4.  Modulation of mutagenesis in eukaryotes by DNA replication fork dynamics and quality of nucleotide pools.

Authors:  Irina S-R Waisertreiger; Victoria G Liston; Miriam R Menezes; Hyun-Min Kim; Kirill S Lobachev; Elena I Stepchenkova; Tahir H Tahirov; Igor B Rogozin; Youri I Pavlov
Journal:  Environ Mol Mutagen       Date:  2012-10-10       Impact factor: 3.216

5.  Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.

Authors:  Alexander J Thompson; Paul J Clark; Abanish Singh; Dongliang Ge; Jacques Fellay; Mingfu Zhu; Qianqian Zhu; Thomas J Urban; Keyur Patel; Hans L Tillmann; Susanna Naggie; Nezam H Afdhal; Ira M Jacobson; Rafael Esteban; Fred Poordad; Eric J Lawitz; Jonathan McCone; Mitchell L Shiffman; Greg W Galler; John W King; Paul Y Kwo; Kevin V Shianna; Stephanie Noviello; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; Mark S Sulkowski; David B Goldstein; John G McHutchison; Andrew J Muir
Journal:  J Hepatol       Date:  2011-05-20       Impact factor: 25.083

6.  Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.

Authors:  Pere Domingo; Josep M Guardiola; Juliana Salazar; Ferran Torres; M Gracia Mateo; Cristina Pacho; M Del Mar Gutierrez; Karuna Lamarca; Angels Fontanet; Jordi Martin; Jessica Muñoz; Francesc Vidal; Montserrat Baiget
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

7.  Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.

Authors:  Alexander J Thompson; Jacques Fellay; Keyur Patel; Hans L Tillmann; Susanna Naggie; Dongliang Ge; Thomas J Urban; Kevin V Shianna; Andrew J Muir; Michael W Fried; Nezam H Afdhal; David B Goldstein; John G McHutchison
Journal:  Gastroenterology       Date:  2010-06-12       Impact factor: 22.682

8.  Elevated Levels of DNA Strand Breaks Induced by a Base Analog in the Human Cell Line with the P32T ITPA Variant.

Authors:  Irina S-R Waisertreiger; Miriam R Menezes; James Randazzo; Youri I Pavlov
Journal:  J Nucleic Acids       Date:  2010-09-26

9.  NUDT16 is a (deoxy)inosine diphosphatase, and its deficiency induces accumulation of single-strand breaks in nuclear DNA and growth arrest.

Authors:  Teruaki Iyama; Nona Abolhassani; Daisuke Tsuchimoto; Mari Nonaka; Yusaku Nakabeppu
Journal:  Nucleic Acids Res       Date:  2010-04-12       Impact factor: 16.971

10.  Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia.

Authors:  G Stocco; M H Cheok; K R Crews; T Dervieux; D French; D Pei; W Yang; C Cheng; C-H Pui; M V Relling; W E Evans
Journal:  Clin Pharmacol Ther       Date:  2008-08-06       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.